List of Vendor Companies in Australia - 40

360biolabs is Australia's most diverse bioanalytical and specialty laboratory offering science-driven expertise and laboratory services for Phase I-III clinical studies. Our advanced laboratories in Melbourne and Brisbane, specialise in using cutting-edge thinking and technology to support the development of novel therapeutics, vaccines and diagnostics. Our global team has laboratories in both the United States and Europe. With our every sample counts mindset, our meticulous attention to detail and adherence to global scientific standards under GLP, GCP and ISO17025 – ensuring the highest level of quality in every clinical trial we undertake. Our quality systems drive method development, tech transfer and assay validation, compliant with ICH, FDA and EMA. 360biolabs has an experienced team of scientists able to conduct a wide array of assays and offers diverse specialist services. Examples include: Pharmacokinetics (PK), Pharmacodynamics (PD), LC/MS, Flow Cytometry, Biomarkers, Molecular Assays, Virology, Central Laboratory services (kit production and lab manuals). __ Follow along in our journey enabling future medicines, or contact our team to learn more about our service offerings and get proposal estimates. Learn more at 360biolabs.com Get in touch via email at: bd@360biolabs.com

Anatomics is a medical technology company that has been manufacturing high-quality medical devices, prosthetics and software solutions since 1995. Based in Melbourne Australia, Anatomics manufactures high quality patient specific implants for global distribution and in-licenses novel technology for Australian and New Zealand distribution. We strive to be recognised as a trusted and innovative provider of quality surgical products. Our mission is to work in partnership with healthcare professionals and medical device companies to provide the highest quality surgical products. We are a company of experienced and dedicated team members who strive for better surgical outcomes by initiating internal product developments and searching the world for the latest innovations in technology to make surgical procedures more effective for our partners and more comfortable for their patients.

Atomo Diagnostics is a medical device manufacturer headquartered in Sydney, Australia with offices in South Africa and the United Kingdom. Atomo Diagnostics was established to capitalise on a core belief that healthcare products offering significantly improved levels of convenience, simplicity and user experience are disproportionately disruptive and have the potential to be very successful commercial market entrants. In 2013, Atomo introduced AtomoRapid, a range of safe, simple professional use tests that deliver fast and accurate results in both clinical and community settings. In 2014, AtomoRapid HIV won Best in Show at the Medical Device Excellence Awards (MDEA) and Atomo was named Australian Emerging Company of the Year for 2014 by Johnson & Johnson Innovation. Atomo is committed to increasing the early detection and ongoing treatment of infectious and chronic diseases by making testing safer, more accurate and more accessible. Visit our website, www.atomodiagnostics.com, for more information on our company and products.

AusDiagnostics Pty Ltd is a leading international company that designs, manufactures and markets a comprehensive suite of multiplexing molecular diagnostic assays and reagents. Founded in August 2006, AusDiagnostics also supports robotic instruments for human diagnostics, animal diagnostics and applied testing. In the past five years, the company has expanded its reach to global customers through offices in New Zealand, the United Kingdom and the United States. In 2018, AusDiagnostics opened a manufacturing facility in the United Kingdom to support the supply of products to its growing network of distribution partners in more than 25 countries. AusDiagnostics continues to develop new technology, and conduct scientific research into innovative diagnostic methodologies for customers around the world.

Avania brings knowledgeable experts together to form a unique CRO that advances the research of medical devices, novel technology, and combination products across a wide range of therapeutic specialties. Our motivated team takes you from feasibility all the way through post-market trials. Our experts in data management and analytics, clinical trial design & execution, strategic consulting, regulatory, reimbursement, and more will provide you with customized, scalable solutions that optimize efficiencies and streamline the advancement of your medical technology. Your product is important, and your company deserves the team that has what it takes. It takes knowledge. It takes passion. It takes commitment. It takes Avania.

Founded in 2003, Base Pharmaceuticals has been a beacon of innovation and quality in the healthcare industry. Our logo, "Reason for Being," symbolizes our dedication to providing life-saving and life-enhancing pharmaceutical solutions. We are committed to improving the quality of life for individuals and communities across North India.

Cardiex Limited (ASX:CDX) is a medical technology company listed on the ASX, focusing on non-invasive vascular health monitoring and digital biomarker solutions for cardiovascular disease management. The company specializes in technologies that measure arterial stiffness and central blood pressure, addressing global cardiovascular health challenges. Cardiex develops FDA-cleared medical devices and digital health solutions aimed at assessing cardiovascular risk, detecting early disease onset, and monitoring treatment efficacy. Its flagship product, the SphygmoCor® system, is recognized for measuring central aortic pressures and arterial stiffness. The company offers services such as clinical decision support, clinical trial solutions, remote patient monitoring, and research partnerships, targeting healthcare providers, clinical trials, researchers, and consumers. With a commitment to reducing the global burden of cardiovascular disease, Cardiex has seen significant revenue growth and has established partnerships to enhance wearable technology adoption. Its product lineup includes the CONNEQT Pulse, a connected vascular biometric monitor, and the Arty™ App for remote patient monitoring, among others.

Founded in 2022, Cauldron is a global biomanufacturer on a mission to realize the full potential of precision fermentation by unlocking price parity for mainstream bio-manufactured goods. By solving historical continuous fermentation challenges to establish a scalable, repeatable continuous process, Cauldron aims to solve the gap in commercially viable biomanufacturing capacity. Developed over more than three decades of R&D, Cauldron's proprietary hyper-fermentation technology drives significant gains in productivity, generating more volume at less cost, using smaller bioreactors. We're operating today at our commercial demo-facility in regional Australia and working with global clients across the precision fermentation industry to de-risk the path to commercialization. Visit www.cauldronferm.com to learn more.

Hear now. And always As the global leader in implantable hearing solutions, at Cochlear (ASX: COH) we are committed to our mission to help people hear and be heard. Our story started more than four decades ago when Professor Graeme Clark pioneered the world's first multi-channel cochlear implant and created an entirely new treatment for hearing loss. Since our formation in 1981, we continue Professor Clark’s work to help people with moderate to profound hearing loss experience a life full of hearing. We have provided more than 650,000 implantable devices. Each recipient helps form a global community of millions, through families, friends, colleagues, teachers and more. And they’re not just connected to their own community — each shares a link with each other and to Professor Clark’s childhood desire to help people hear. We aim to give people the best lifelong hearing experience and access to innovative future technologies. We understand the privilege of connecting people to a life lived with hearing. And we listen, respond and move with the times – to continue to bring hearing within reach of all those who need it. That's how we live our mission every day. Our global workforce of more than 4,000 people shares a collective determination to give more people the opportunity to enjoy a life of hearing. Cochlear’s global headquarters are on the campus of Macquarie University in Sydney, Australia with regional headquarters in Asia Pacific, Europe and the Americas. Through our offices in over 180 countries we help people of all ages to hear. Social Media Terms of Use http://bit.ly/2qRMEvY

Coloplast develops products & services for people with stoma, bladder & bowel & wound care problems. Try a free sample today.

As a leading radiopharmaceutical manufacturer in Australia and New Zealand, our mission at Cyclotek is to improve patient outcomes with accessible targeted radiopharmaceuticals. Our novel PET-tracers provide patient-specific insights into their disease state, providing earlier diagnosis, more accurate assessment of disease extent and improved treatment planning and motoring. Cyclotek offers a range of radiopharmaceutical products in oncology and neurology, bringing patient-centred diagnostics to life. With the unlocking of the human genome and ever more sophisticated chemistry innovation, we seek to advance therapeutic discovery, further refine diagnostic pathways and drive higher standards in personalised medicine.

Datapharm is Australia's original independent full-service Contract Research Organisation (CRO), est. 1987, providing clinical trial management, design, site set-up, monitoring, statistical services, data management (including eCRFs), medical writing, pharmacovigilance and auditing. Datapharm has earned an enviable reputation for quality, following involvement in hundreds of clinical trials in over 35 therapeutic areas, Phases I (including first-in-human) to IV, for Big Pharma, Biotech, Medical Device companies and Non-profit organisations. Datapharm works to ICH GCP and international regulatory authority standards with an overlay of excellent project management to achieve project milestones. Datapharm offers services internationally through the global CRO consortium DAI-SYS.

Ellume is an Australian based Health Technology company that develops and manufactures connected real-time diagnostics for doctors and consumers. We achieve this by combining next-generation quantum dot diagnostics with connected care technologies. Our products are distinguished by their simplicity of design, ease of use, rapid time to result and connectivity. To learn more about Ellume, visit our website at www.ellumehealth.com.

Ferronova is an innovative medical device company, which has brought together a patented magnetic probe from the University of South Australia and iron magnetic nanoparticle technology from Victoria University of Wellington, to produce an advanced diagnostic system to improve the detection of cancer metastases. Ferronova has research collaborations with UniSA Future Industries Institute, the University of Sydney, and the University of New South Wales. Founded in 2016, Ferronova is backed by Uniseed, Artesian Ventures, ASX-listed investment group Powerhouse Ventures, PAN Ventures, UniSA Ventures and Wellington UniVentures. The South Australian government and Australian government have provided grant funding to develop the technology.

Gelomics is revolutionizing drug development by enabling the growth of human tissue models in vitro, providing an ethical, cost-effective, and predictive alternative to animal testing. Our mission is to accelerate therapeutic breakthroughs, ensuring faster, safer, and more humane medical advancements.

We are a global biotechnology company specialising in ingestible gel technologies for humans and animals, covering the pharmaceutical, healthcare, nutrition & sport sectors. Our proprietary technology has been designed to assist with the delivery of APIs (active pharmaceutical ingredients) or nutritional compounds via an easy to consume gel based formulation. We provide a unique gel based technology for clients who are looking to offer an alternative to pills, powders and capsules. If you are looking to innovate the way you can deliver improved health to your clients, please get in touch.

Genetype - Unlocking personalised preventative health Genetic Technologies (ASX: GTG, NASDAQ Global Market: GENE) is a leader in the development and commercialisation of genetic risk assessment technology. Significant progress has been made in understanding the role of hereditary risk in chronic disease, however, many chronic conditions cannot be predicted by this risk alone. We’re transforming the conversation. Transitioning from a one-size-fits-all model to personalised, predictive health assessment – where each person has the information, they need to manage their health according to their own risk.

With over 25 years experience in the Australian Genomics industry, GeneWorks has a proud history of instrument and consumable sales and service, excellence in post sales support, and manufacture of bespoke isothermal nucleic acid assays here in Australia at our Melbourne facility. More recently, our partnership with AKOYA Biosciences and Quanterix provides Australian and New Zealand researchers and clinicians access to the latest in spatial phenotyping and ultra sensitive biomarker detection. In addition GeneWorks also proudly represents - Art Robbins Instruments - Protein crystallography - LGC Genomics - Genotyping reagents and services (KASP and sbeadex) - Nippon Genetics - Molecular biology (Midori) - OptiGene - Isothermal amplification technology (Genie Instrument and LAMP) Our team of Scientific sales professionals, together with expert support and service engineering staff have a genuine passion for our mission to provide the latest instrument and reagent options to the Australian Biotechnology Industry.

George Clinical is a clinical research organization that provides healthcare services and conducts medical trials for the pharmaceutical industry.

Founded in 1975, IDT Australia is a publicly listed Australian pharmaceutical manufacturing company, based in Boronia Victoria. Our experienced and awarded team of scientists and specialists provide a flexible and comprehensive service, focussed in our three strategic pillars: Active Pharmaceutical Ingredient synthesis design, scale up and cGMP manufacture including high potent molecules Specialty Orals novel and early stage design, formulation and cGMP manufacturing specifically targeting neuro disorders Advanced Technology, complex formulations for novel injectable drug development through to cGMP manufacture. This pillar includes RNA and Antibody Drug Conjugates. IDT Australia also has a fully equipped laboratory approved to TGA and FDA standards to develop, validate and operate GLP analytics for release, process validation and stability. IDT Australia has labelling and packaging capacity and capability and specialises in clinical trial labelling and packing.

▶ WHAT WE DO: iNGENū CRO delivers FDA-compliant clinical trials for US Biotechs and saves them 70% of their clinical trial costs... WITHOUT the lengthy timelines typically associated with clinical trials. We manage all the heavy lifting to ensure that our clients can focus on what they do best – creating life-saving treatments. ▶ OUR FDA-EXCLUSIVE FOCUS: As a full-service CRO, our team members have the experience of hundreds of clinical trials behind them. Our unique, FDA-exclusive focus has created a CRO performing: 1. Clinical Trials (Phase I, II, and III) 2. IND-Enabling Non-Clinical Studies with Data in FDA-Compliant SEND Format 3. FDA Regulatory Submissions (PIND, IND, NDA) ▶ WHY WORK WITH US: 1. Government Grant Access: As an Australian CRO, all our clients (clinical and non-clinical) will receive up to 43.5% government R&D Incentive to perform their research with us. 2. Fast, High-Quality Research: We excel in conducting fast-paced research that strictly adheres to FDA guidelines and regulations. We ensure that our clients' timelines are met without sacrificing quality. 3. FDA Regulatory Expertise: With extensive experience in FDA regulatory work, we specialize in making full FDA pre-IND and IND submissions for our clients. 4. Diverse Therapeutic Specialty Leaders: Our team comprises physician and scientific specialists with expertise in a wide variety of therapeutic areas, enabling us to provide highly tailored solutions that meet the unique demands of your clinical trials. ▶ OUR TYPICAL CLIENT: An early-stage US biotech company who is looking for: • >70% cost reduction on FDA-compliant clinical and nonclinical trials • All data being 21 CFR 312.120 compliant for US FDA submission • Clinical trial startup time in 8-10 weeks • Commence FIH clinical trials prior to opening an IND • Perform rodent and second-species nonclinical studies at a fraction of the cost of the US ▶ READY TO TALK? ☎️ Like to find out more? Book a time to connect with us.

▶ WHAT WE DO: iNGENū CRO delivers FDA-compliant clinical trials for US Biotechs and saves them 70% of their clinical trial costs... WITHOUT the lengthy timelines typically associated with clinical trials. We manage all the heavy lifting to ensure that our clients can focus on what they do best – creating life-saving treatments. ▶ OUR FDA-EXCLUSIVE FOCUS: As a full-service CRO, our team members have the experience of hundreds of clinical trials behind them. Our unique, FDA-exclusive focus has created a CRO performing: 1. Clinical Trials (Phase I, II, and III) 2. IND-Enabling Non-Clinical Studies with Data in FDA-Compliant SEND Format 3. FDA Regulatory Submissions (PIND, IND, NDA) ▶ WHY WORK WITH US: 1. Government Grant Access: As an Australian CRO, all our clients (clinical and non-clinical) will receive up to 43.5% government R&D Incentive to perform their research with us. 2. Fast, High-Quality Research: We excel in conducting fast-paced research that strictly adheres to FDA guidelines and regulations. We ensure that our clients' timelines are met without sacrificing quality. 3. FDA Regulatory Expertise: With extensive experience in FDA regulatory work, we specialize in making full FDA pre-IND and IND submissions for our clients. 4. Diverse Therapeutic Specialty Leaders: Our team comprises physician and scientific specialists with expertise in a wide variety of therapeutic areas, enabling us to provide highly tailored solutions that meet the unique demands of your clinical trials. ▶ OUR TYPICAL CLIENT: An early-stage US biotech company who is looking for: • >70% cost reduction on FDA-compliant clinical and nonclinical trials • All data being 21 CFR 312.120 compliant for US FDA submission • Clinical trial startup time in 8-10 weeks • Commence FIH clinical trials prior to opening an IND • Perform rodent and second-species nonclinical studies at a fraction of the cost of the US ▶ READY TO TALK? ☎️ Like to find out more? Book a time to connect with us.

Inventia Life Science is making advanced cell models easy for high impact discovery. The company's strong foundation of fundamental research has led to the development of proprietary solutions to generate high-quality advanced cell models that are reproducible and highly consistent. Built by scientists for scientists, our intuitive solutions integrate seamlessly with existing workflows, whereas our wide range of biofunctional synthetic matrices and application-driven models make your desired assays possible.

LBT Innovations is a medical technology company that utilizes artificial intelligence to deliver automation in healthcare through a patent-protected machine learning and intelligent imaging platform.

Delivery system for recombinant protein vaccine

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase. Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006. The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice. For more information or to speak to an expert team member visit www.Novotech-CRO.com

OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy. OncoSil Medical's lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel. OncoSil™ is designated as a breakthrough device in both Europe and the United States¹. We believe in our technology and its ability to have a truly positive impact in Oncology. OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications. Website link: oncosil.com References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.

Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacture and commercialisation of endomicroscopic digital imaging technology solutions for medical, translational and pre-clinical applications. Our unique technology offers real-time, 3D, in vivo imaging at the single-cell level, in a non-destructive manner that enables clinicians to make immediate informed decisions. We are driven by delivering digital healthcare solutions giving healthcare providers and researchers high quality, live, microscopic images and associated tools. Our technology helps facilitate earlier detection and management of disease thus improving patient outcomes and reducing the cost of curative medicine and associated procedures within healthcare systems. We are united in the common pursuit of revolutionising healthcare with live digital microscopic solutions that enable immediate informed decisions, provide economic efficiencies within health systems and improve patient outcomes.

Orivet genetics is a specialized laboratory with a mission to safeguard the health and wellbeing of pets with fully personalized, breed-specific care. Orivet was founded on the premise that each and every pet is unique, with its own set of specific traits, behaviours, genetic health needs and inherent risks. We work with pet owners, breeders and veterinarians to provide completely personalized products and services that treat and care for pets as the unique individuals they are, taking into account each pet's genetic makeup, age, sex and lifestyle. Through this we aim to encourage the development of a deep, genuine and lasting bond between pets and their owners. Orivet operates in 3 distinct fields: We help veterinary doctors provide pets with customized preventative and protective medicine, looking out for specific genetic health conditions which can lead to early diagnosis and more effective treatment. We work closely with pet animal breeders by promoting responsible breeding. We offer an extensive range of molecular (DNA) tests and services including screening for genetic disease. The main beneficiaries of this strategy are healthier animals for generations to come. We help pet owners learn about their pets' special nature and needs through the most up-to-date information and tools. Our products and services are designed to provide the highest quality and most relevant nutritional, behavioural and healthcare support for pets. Orivet is committed to eradicating animal cruelty wherever it may be on our planet. Our products are made from all natural ingredients, free from any artificial additives and have not been tested on animals.

Ozgene offers the full spectrum of capabilities to design, generate, breed & phenotype your mouse models. It was not that long ago that a mouse was just a mouse but, for the team at Ozgene, a mouse represents a way to advance humanity. Started 15 years ago, today, Ozgene is one of the leading companies providing genetically customised mice for researchers around the world. With best in industry timelines using their goGermline embryos other services include knock-in, knockout, humanized and transgenic mouse models, breeding and husbandry, validation and phenotyping and Geneoz VMS. Ozgene has developed a new goGermline approach, which is a revolutionary new technology to generate knockout and knock-in mice fast and efficiently, while improving animal welfare. Ozgene is now able to complete projects in less than 6 months. Whilst, Ozgene is an Australian company, 80% of their clients are located overseas and shipments leave the Ozgene facility almost daily for laboratories, small academic institutions, research institutes, biotechnology companies and multinational pharmaceutical companies in the US, Europe, Asia, South America and New Zealand. CEO and Co-founder, Dr Frank Koentgen, and the Ozgene team have over 20 years of experience in the generation of genetically modified mice. It begins even before Ozgene was born, when Dr Koentgen generated the first knockout mouse from the C57BL/6 mouse strain in 1993. Work has been published in scientific journals such as Cell, Nature, Science, Immunity, PNAS and Nature Medicine.

PolyNovo is a disruptive ASX 200 medical technology company. Its products simplify managing acute complex wounds, redefining healing with differentiated outcomes across many etiologies. After treating 50,000+ patients across 42 countries, the company is investing for growth via new products, indications and markets with a view to treat millions more. Our registered address is 2/320 Lorimer St, Port Melbourne, Victoria 3207, Australia.

Proteomics International Laboratories Limited (ASX:PIQ) is a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease. Proteomics International is now implementing a stepped rollout of PromarkerD, its flagship diagnostic test for diabetic kidney disease, globally. Successful commercialisation of this diagnostic test is expected to bolster Proteomics' revenue base. PromarkerD licensing fees and royalty payments will rise as the test is adopted by more physicians and licensed into new geographic regions. The Company is, at the same time, continuing to research potential diagnostic tests for other diseases, including endometriosis, asthma, COPD, oesophageal cancer, Diabetic retinopathy and oxidative stress. Proteomics' Analytical Services unit provides fee-for-service revenue, which helps financially support the Company's commercialisation and research activities. To learn more please visit: www.proteomics.com.au/

Provectus Algae specializes in optimizing the production of microalgae species. The microalgae produce high-value biobased chemicals, specialty ingredients, and biologics for use in a wide array of industries and applications.

Sonic Genetics, launched in 2014, is one of the most significant initiatives introduced by Sonic Healthcare, and is responsible for overseeing all genetic testing throughout Sonic. Sonic Genetics gives doctors and patients access to an extensive range of genetic tests, provided through Sonic Healthcare's network of Australian and international laboratories. The purpose of Sonic Genetics is to enable a national provision and promotion of genetic testing services by Sonic, with a goal to becoming the national leader in provision of clinically relevant genetic diagnostic services in Australia. We are actively growing our assay menu, with significant plans for expansion to match demand and market need.

Synchron is a Brain Computer Interface company based in Campbell, California and Melbourne, Australia. We are developing minimally-invasive technology for safe and rapid implantation of miniaturized electronic medical devices with broadband capability.

SYNkinase's mission is to provide life-science researchers with access to the world's most up-to-date library of kinase inhibitors, and other small molecule inhibitors of important therapeutic proteins, for drug-discovery research use. With guidance from our founders, that include kinase biology scientists and expert medicinal and synthetic chemists, we have created a library of potent, pure and research-relevant inhibitors directed against specific protein serine/threonine kinases (PS/TKs), protein tyrosine kinases (PTK & RTK), as well as lipid kinases. There are more than 150 Kinase targeted drugs in clinical trials or development at present. Twenty four small molecule inhibitors have been FDA-approved including mTOR, B-Raf, MEK, EGFR, JAK, VEGFR and PI3K inhibitors. SYNkinase has many of these compounds available for sale as well as a large range of inhibitors described in the literature such as GPCR and epigenetic inhibitors. Importantly, as we are a primary source manufacturer we can maintain a fastidious focus on quality, as well as being first in the market with the most important and topical compounds. SYNkinase offers its inhibitor collections in several formats, including pre-formatted and custom arrays.

TGR BioSciences is an Australian biotechnology company, specializing in the development and manufacture of immunoassays and immunoassay technologies. TGR's CaptSure technology underpins its immunoassay products and is available for license.

Science can do great things. With the right vision, tools and people, science can improve human health. At Trajan, we focus on the good science can deliver to impact our wellbeing. Our goal is to collaborate with academic and industry partners to develop innovative products for scientific and medical analysis. From sample sources to laboratories to individuals, Trajan makes scientific analytical systems more selective, sensitive and specific in measurements for biological, environmental and food samples. We are advancing scientific tools and chemistry to improve the quality of data labs get from their samples. Trajan is especially interested in technologies that can lead to portability, miniaturization and affordability - making science more accessible. Our driving force is better health for the future – and delivering breakthrough solutions to the world. Join us on our analytical and medical science journey. Together, let's enhance the wellbeing of our communities. Trajan employs a global workforce with operations in Australia, Europe, the US and Asia.

Universal Biosensors Inc (UBI) is a global biosensor company and a world leader in electrochemical cell technology. UBI's ambition is to utilize its patented biosensor technology to develop a diverse range of biosensor test strips used in our hand-held portable analyzers; for cost effective, effortless, and accurate detection of analytes of interest, within many industries including human health, animal health, environmental, and agriculture. UBI is a USA Delaware company listed on the Australian Securities Exchange (ASX:UBI) and operates from its head office, manufacturing facility, and research laboratory in Melbourne, Victoria, Australia. In 2021, UBI successfully launched its unique handheld wine analyzer called Sentia™ with an initial test to measure free SO2 , and subsequently in 2022, tests for monitoring malic acid and glucose throughout the wine production process (more tests in the pipeline are due for release in late 2022). In 2022, UBI launched Xprecia Prime™ in the EU and UK, the next-generation blood coagulation analyzer which replaces Xprecia Stride™. Xprecia Prime™ is due for launch in the US in 2023. UBI is due to launch Petrackr™ in late 2022/early 2023, a veterinary blood glucometer to monitor diabetes in cats and dogs. These products will complement UBI's existing Canadian blood testing laboratory Hemostasis Reference Lab (HRL).

About Vestech Medical Device innovation and commercialisation is fraught with risk, missteps and wastage. Navigating the successful passage of a device from invention to commercial success is Vestech's area of expertise. Understanding the landscape, working with innovators and providing collaborative advice are key components of our day to day activities. Experience & Process When it comes to Medical Device development and commercialisation, nothing beats experience. Vestech has that hands on experience and more. Vestech and its team have been in the field of medical device commercialisation for more than 30 years. During that time Vestech has accumulated direct and personal experience in the following areas: The technical aspects of device design The regulatory requirements Intellectual property protection Liaising with tertiary institutions Business planning Reimbursement strategies Export development International regulations and systems Capital raising Listed entities management Legal requirements Human resource development Industry organisation engagement Federal and state policy development and lobbying Project management Exit strategies During the realisation of a medical device project, Vestech works with Australia's top specialist vendors and consultants to assure a first class result. Vestech's connections within Australia and Internationally have been built up and tested over decades to ensure "no surprises" delivery.